+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Systemic Lupus Erythematosus Treatment Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2019 - 2027

  • ID: 4911406
  • Report
  • October 2019
  • Region: Global
  • 211 pages
  • Transparency Market Research
1 of 3

FEATURED COMPANIES

  • AstraZeneca plc
  • F. Hoffmann-La Roche Ltd.
  • GlaxoSmithKline plc
  • ImmuPharma PLC
  • Merck & Co., Inc.
  • Pfizer, Inc.
  • MORE
Systemic Lupus Erythematosus Treatment Market - Scope of the Report

the report on the global systemic lupus erythematosus treatment market studies the past as well as current growth trends and opportunities, to gain valuable insights of the indicators for the said market for the forecast period of 2019 to 2027. The report provides the overall market revenue of the global systemic lupus erythematosus treatment market for the period of 2017-2027, considering 2018 as the base year and 2027 as the forecast year. The report also provides the compound annual growth rate (CAGR %) of the global systemic lupus erythematosus treatment market from 2019 to 2027.

The report is prepared after extensive research. Primary research involved bulk of the research efforts, wherein, analysts carried out interviews with key opinion leaders, industry leaders, and opinion makers. Extensive secondary research involved reaching out to key players’ product literature, annual reports, press releases, and relevant documents to understand the systemic lupus erythematosus treatment market.

Secondary research also includes Internet sources, statistical data from government agencies, websites, and trade associations. Analysts employed a combination of the top-down and bottom-up approach to study the various attributes of the systemic lupus erythematosus treatment market.

The report includes an elaborate executive summary along with a snapshot of the growth behavior of various segments and sub-segments included in the scope of the study. Moreover, the report throws light on the changing competitive dynamics in the global systemic lupus erythematosus treatment market. These serve as valuable tools for existing market players as well as for entities interested in participating in the global systemic lupus erythematosus treatment market.

The report delves into the competitive landscape of the global systemic lupus erythematosus treatment market. Key players operating in the global systemic lupus erythematosus treatment market are identified and each one of them is profiled in terms of various attributes. Company overviews, financial standings, recent developments, and SWOT are the attributes of players in the global systemic lupus erythematosus treatment market that are profiled in this report.

Key Questions Answered in the Systemic Lupus Erythematosus Treatment Market Report
  • What is the sales/revenue expected to be generated by systemic lupus erythematosus treatment across all regions during the forecast period?
  • What are the opportunities in the systemic lupus erythematosus treatment market?
  • What are the major drivers, restraints, opportunities, and threats in the market?
  • Which region is set to expand at the fastest CAGR during the forecast period?
  • Which product segment is expected to generate the highest revenue, globally, in 2027? Which segment is projected to expand at the highest CAGR during the forecast period?
  • What are the market positions of different companies operating in the global market?
Research Objectives and Research Approach

The comprehensive report on the global systemic lupus erythematosus treatment market begins with an overview, followed by the scope and objectives of the study. Following this, the report provides detailed explanation of the objectives behind this study, key vendors and distributors operating in the market, and regulatory scenario for the approval of products.

For reading comprehensibility, the report has been compiled in a chapter-wise layout, with each section divided into smaller sections. The report comprises an exhaustive collection of graphs and tables that are appropriately interspersed. Pictorial representation of actual and projected values of key segments is visually appealing to the readers. This also allows comparison of the market shares of key segments in the past and at the end of the forecast period
Note: Product cover images may vary from those shown
2 of 3

FEATURED COMPANIES

  • AstraZeneca plc
  • F. Hoffmann-La Roche Ltd.
  • GlaxoSmithKline plc
  • ImmuPharma PLC
  • Merck & Co., Inc.
  • Pfizer, Inc.
  • MORE
1. Preface
1.1. Report Scope and Market Segmentation
1.2. Research Highlights

2. Assumptions and Research Methodology
2.1. Assumptions
2.2. Research Methodology

3. Executive Summary
3.1. Global Systemic Lupus Erythematosus Treatment Market Snapshot

4. Market Overview
4.1. Product Overview
4.2. Key Industry Events
4.3. Market Dynamics
4.3.1. Drivers and Restraints Snapshot Analysis
4.3.2. Drivers
4.3.3. Restraints
4.3.4. Opportunities
4.4. Global Systemic Lupus Erythematosus Treatment Market Revenue Projection
4.5. Global Systemic Lupus Erythematosus Treatment Market Outlook

5. Market Outlook
5.1. Key Mergers & Acquisitions
5.2. Pipeline Analysis
5.3. Disease Prevalence & Incidence Rate Globally with Key Countries

6. Global Systemic Lupus Erythematosus Treatment Market Analysis, by Drug
6.1. Introduction
6.2. Global Systemic Lupus Erythematosus Treatment Market Value Share and Attractiveness Analysis, by Drug
6.3. Global Systemic Lupus Erythematosus Treatment Market Forecast, by Drug
6.3.1. Antimalarial Drugs
6.3.1.1. Chloroquine
6.3.1.2. Hydrochloroquine
6.3.2. Non-steroidal Anti-inflammatory Drugs (NSAIDS)
6.3.2.1. Ibuprofen
6.3.2.2. Naproxen
6.3.2.3. Others
6.3.3. Corticosteroids
6.3.3.1. Prednisone
6.3.3.2. Hydrocortisone
6.3.3.3. Dexamethasone
6.3.3.4. Others
6.3.4. Immunosuppressive Drugs
6.3.4.1. Azathioprine
6.3.4.2. Cyclophosphamide
6.3.4.3. Methotrexate
6.3.4.4. Others
6.3.5. Others (Biologics, B-cell Modulators, etc.)

7. Global Systemic Lupus Erythematosus Treatment Market Analysis, by Mode of Delivery
7.1. Introduction
7.2. Global Systemic Lupus Erythematosus Treatment Market Value Share and Attractiveness Analysis, by Mode of Delivery
7.3. Global Systemic Lupus Erythematosus Treatment Market Forecast, by Mode of Delivery
7.3.1. Intravenous
7.3.2. Subcutaneous
7.3.3. Oral
7.4. Global Systemic Lupus Erythematosus Treatment Market Analysis, by Mode of Delivery

8. Global Systemic Lupus Erythematosus Treatment Market Analysis, by Distribution Channel
8.1. Introduction
8.2. Global Systemic Lupus Erythematosus Treatment Market Value Share and Attractiveness Analysis, by Distribution Channel
8.3. Global Systemic Lupus Erythematosus Treatment Market Forecast, by Distribution Channel
8.3.1. Hospital Pharmacies
8.3.2. Retail Pharmacies
8.3.3. Online Sales
8.4. Global Systemic Lupus Erythematosus Treatment Market Analysis, by Distribution Channel

9. Global Systemic Lupus Erythematosus Treatment Market Analysis, by Region
9.1. Global Systemic Lupus Erythematosus Treatment Market Scenario, by Country
9.2. Global Systemic Lupus Erythematosus Treatment Market Value Share and Attractiveness Analysis, by Region
9.3. Global Systemic Lupus Erythematosus Treatment Market Forecast, by Region
9.3.1. North America
9.3.2. Europe
9.3.3. Asia Pacific
9.3.4. Latin America
9.3.5. Middle East & Africa

10. North America Systemic Lupus Erythematosus Treatment Market Analysis
10.1. Key Findings
10.2. North America Systemic Lupus Erythematosus Treatment Market Overview
10.3. North America Systemic Lupus Erythematosus Treatment Market Value Share and Attractiveness Analysis, by Country
10.4. North America Systemic Lupus Erythematosus Treatment Market Forecast, by Country
10.4.1. U.S.
10.4.2. Canada
10.5. North America Systemic Lupus Erythematosus Treatment Market Value Share and Attractiveness Analysis, by Drug
10.6. North America Systemic Lupus Erythematosus Treatment Market Forecast, by Drug
10.6.1. Antimalarial Drugs
10.6.1.1. Chloroquine
10.6.1.2. Hydrochloroquine
10.6.2. Non-steroidal Anti-inflammatory Drugs (NSAIDS)
10.6.2.1. Ibuprofen
10.6.2.2. Naproxen
10.6.2.3. Others
10.6.3. Corticosteroids
10.6.3.1. Prednisone
10.6.3.2. Hydrocortisone
10.6.3.3. Dexamethasone
10.6.3.4. Others
10.6.4. Immunosuppressive Drugs
10.6.4.1. Azathioprine
10.6.4.2. Cyclophosphamide
10.6.4.3. Methotrexate
10.6.4.4. Others
10.6.5. Others (Biologics, B-cell Modulators, etc.)
10.7. North America Systemic Lupus Erythematosus Treatment Market Value Share Analysis, by Mode of Delivery
10.8. North America Systemic Lupus Erythematosus Treatment Market Value (US$ Mn) Forecast, by Mode of Delivery
10.8.1. Intravenous
10.8.2. Subcutaneous
10.8.3. Oral
10.9. North America Systemic Lupus Erythematosus Treatment Market Value Share and Attractiveness Analysis, by Distribution Channel
10.10. North America Systemic Lupus Erythematosus Treatment Market Forecast, by Distribution Channel
10.10.1. Hospital Pharmacies
10.10.2. Retail Pharmacies
10.10.3. Online Sales

11. Europe Systemic Lupus Erythematosus Treatment Market Analysis
11.1. Key Findings
11.2. Europe Systemic Lupus Erythematosus Treatment Market Overview
11.3. Europe Systemic Lupus Erythematosus Treatment Market Value Share and Attractiveness Analysis, by Country/Sub-region
11.4. Europe Systemic Lupus Erythematosus Treatment Market Forecast, by Country/Sub-region
11.4.1. Germany
11.4.2. U.K.
11.4.3. France
11.4.4. Spain
11.4.5. Italy
11.4.6. Rest of Europe
11.5. Europe Systemic Lupus Erythematosus Treatment Market Value Share and Attractiveness Analysis, by Drug
11.6. Europe Systemic Lupus Erythematosus Treatment Market Forecast, by Drug
11.6.1. Antimalarial Drugs
11.6.1.1. Chloroquine
11.6.1.2. Hydrochloroquine
11.6.2. Non-steroidal Anti-inflammatory Drugs (NSAIDS)
11.6.2.1. Ibuprofen
11.6.2.2. Naproxen
11.6.2.3. Others
11.6.3. Corticosteroids
11.6.3.1. Prednisone
11.6.3.2. Hydrocortisone
11.6.3.3. Dexamethasone
11.6.3.4. Others
11.6.4. Immunosuppressive Drugs
11.6.4.1. Azathioprine
11.6.4.2. Cyclophosphamide
11.6.4.3. Methotrexate
11.6.4.4. Others
11.6.5. Others (Biologics, B-cell Modulators, etc.)
11.7. Europe Systemic Lupus Erythematosus Treatment Market Value Share Analysis, by Mode of Delivery
11.8. Europe Systemic Lupus Erythematosus Treatment Market Value (US$ Mn) Forecast, by Mode of Delivery
11.8.1. Intravenous
11.8.2. Subcutaneous
11.8.3. Oral
11.9. Europe Systemic Lupus Erythematosus Treatment Market Value Share and Attractiveness Analysis, by Distribution Channel
11.10. Europe Systemic Lupus Erythematosus Treatment Market Forecast, by Distribution Channel
11.10.1. Hospital Pharmacies
11.10.2. Retail Pharmacies
11.10.3. Online Sales

12. Asia Pacific Systemic Lupus Erythematosus Treatment Market Analysis
12.1. Key Findings
12.2. Asia Pacific Systemic Lupus Erythematosus Treatment Market Overview
12.3. Asia Pacific Systemic Lupus Erythematosus Treatment Market Value Share and Attractiveness Analysis, by Country/Sub-region
12.4. Asia Pacific Systemic Lupus Erythematosus Treatment Market Forecast, by Country/Sub-region
12.4.1. Japan
12.4.2. China
12.4.3. India
12.4.4. Australia & New Zealand
12.4.5. Rest of Asia Pacific
12.5. Asia Pacific Systemic Lupus Erythematosus Treatment Market Value Share and Attractiveness Analysis, by Drug
12.6. Asia Pacific Systemic Lupus Erythematosus Treatment Market Forecast, by Drug
12.6.1. Antimalarial Drugs
12.6.1.1. Chloroquine
12.6.1.2. Hydrochloroquine
12.6.2. Non-steroidal Anti-inflammatory Drugs (NSAIDS)
12.6.2.1. Ibuprofen
12.6.2.2. Naproxen
12.6.2.3. Others
12.6.3. Corticosteroids
12.6.3.1. Prednisone
12.6.3.2. Hydrocortisone
12.6.3.3. Dexamethasone
12.6.3.4. Others
12.6.4. Immunosuppressive Drugs
12.6.4.1. Azathioprine
12.6.4.2. Cyclophosphamide
12.6.4.3. Methotrexate
12.6.4.4. Others
12.6.5. Others (Biologics, B-cell Modulators, etc.)
12.7. Asia Pacific Systemic Lupus Erythematosus Treatment Market Value Share Analysis, by Mode of Delivery
12.8. Asia Pacific Systemic Lupus Erythematosus Treatment Market Value (US$ Mn) Forecast, by Mode of Delivery
12.8.1. Intravenous
12.8.2. Subcutaneous
12.8.3. Oral
12.9. Asia Pacific Systemic Lupus Erythematosus Treatment Market Value Share and Attractiveness Analysis, by Distribution Channel
12.10. Asia Pacific Systemic Lupus Erythematosus Treatment Market Forecast, by Distribution Channel
12.10.1. Hospital Pharmacies
12.10.2. Retail Pharmacies
12.10.3. Online Sales

13. Latin America Systemic Lupus Erythematosus Treatment Market Analysis
13.1. Key Findings
13.2. Latin America Systemic Lupus Erythematosus Treatment Market Overview
13.3. Latin America Systemic Lupus Erythematosus Treatment Market Value Share and Attractiveness Analysis, by Country/Sub-region
13.4. Latin America Systemic Lupus Erythematosus Treatment Market Forecast, by Country/Sub-region
13.4.1. Brazil
13.4.2. Mexico
13.4.3. Rest of Latin America
13.5. Latin America Systemic Lupus Erythematosus Treatment Market Value Share and Attractiveness Analysis, by Drug
13.6. Latin America Systemic Lupus Erythematosus Treatment Market Forecast, by Drug
13.6.1. Antimalarial Drugs
13.6.1.1. Chloroquine
13.6.1.2. Hydrochloroquine
13.6.2. Non-steroidal Anti-inflammatory Drugs (NSAIDS)
13.6.2.1. Ibuprofen
13.6.2.2. Naproxen
13.6.2.3. Others
13.6.3. Corticosteroids
13.6.3.1. Prednisone
13.6.3.2. Hydrocortisone
13.6.3.3. Dexamethasone
13.6.3.4. Others
13.6.4. Immunosuppressive Drugs
13.6.4.1. Azathioprine
13.6.4.2. Cyclophosphamide
13.6.4.3. Methotrexate
13.6.4.4. Others
13.6.5. Others (Biologics, B-cell Modulators, etc.)
13.7. Latin America Systemic Lupus Erythematosus Treatment Market Value Share Analysis, by Mode of Delivery
13.8. Latin America Systemic Lupus Erythematosus Treatment Market Value (US$ Mn) Forecast, by Mode of Delivery
13.8.1. Intravenous
13.8.2. Subcutaneous
13.8.3. Oral
13.9. Latin America Systemic Lupus Erythematosus Treatment Market Value Share and Attractiveness Analysis, by Distribution Channel
13.10. Latin America Systemic Lupus Erythematosus Treatment Market Forecast, by Distribution Channel
13.10.1. Hospital Pharmacies
13.10.2. Retail Pharmacies
13.10.3. Online Sales

14. Middle East & Africa Systemic Lupus Erythematosus Treatment Market Analysis
14.1. Key Findings
14.2. Middle East & Africa Systemic Lupus Erythematosus Treatment Market Overview
14.3. Middle East & Africa Systemic Lupus Erythematosus Treatment Market Value Share and Attractiveness Analysis, by Country/Sub-region
14.4. Middle East & Africa Systemic Lupus Erythematosus Treatment Market Forecast, by Country/Sub-region
14.4.1. GCC Countries
14.4.2. South Africa
14.4.3. Rest of Middle East & Africa
14.5. Middle East & Africa Systemic Lupus Erythematosus Treatment Market Value Share and Attractiveness Analysis, by Drug
14.6. Middle East & Africa Systemic Lupus Erythematosus Treatment Market Forecast, by Drug
14.6.1. Antimalarial Drugs
14.6.1.1. Chloroquine
14.6.1.2. Hydrochloroquine
14.6.2. Non-steroidal Anti-inflammatory Drugs (NSAIDS)
14.6.2.1. Ibuprofen
14.6.2.2. Naproxen
14.6.2.3. Others
14.6.3. Corticosteroids
14.6.3.1. Prednisone
14.6.3.2. Hydrocortisone
14.6.3.3. Dexamethasone
14.6.3.4. Others
14.6.4. Immunosuppressive Drugs
14.6.4.1. Azathioprine
14.6.4.2. Cyclophosphamide
14.6.4.3. Methotrexate
14.6.4.4. Others
14.6.5. Others (Biologics, B-cell Modulators, etc.)
14.7. Middle East & Africa Systemic Lupus Erythematosus Treatment Market Value Share Analysis, by Mode of Delivery
14.8. Middle East & Africa Systemic Lupus Erythematosus Treatment Market Value (US$ Mn) Forecast, by Mode of Delivery
14.8.1. Intravenous
14.8.2. Subcutaneous
14.8.3. Oral
14.9. Middle East & Africa Systemic Lupus Erythematosus Treatment Market Value Share and Attractiveness Analysis, by Distribution Channel
14.10. Middle East & Africa Systemic Lupus Erythematosus Treatment Market Forecast, by Distribution Channel
14.10.1. Hospital Pharmacies
14.10.2. Retail Pharmacies
14.10.3. Online Sales

15. Competitive Landscape
15.1. Competition Matrix
15.2. Company Profile
15.2.1. GlaxoSmithKline plc
15.2.1.1. Company Overview (HQ, Business Segments, Employee Strength)
15.2.1.2. Financial Overview
15.2.1.3. Product Portfolio
15.2.1.4. SWOT Analysis
15.2.1.5. Strategic Overview
15.2.2. F. Hoffmann-La Roche Ltd.
15.2.2.1. Company Overview (HQ, Business Segments, Employee Strength)
15.2.2.2. Financial Overview
15.2.2.3. Product Portfolio
15.2.2.4. SWOT Analysis
15.2.2.5. Strategic Overview
15.2.3. Pfizer, Inc.
15.2.3.1. Company Overview (HQ, Business Segments, Employee Strength)
15.2.3.2. Financial Overview
15.2.3.3. Product Portfolio
15.2.3.4. SWOT Analysis
15.2.3.5. Strategic Overview
15.2.4. AstraZeneca plc
15.2.4.1. Company Overview (HQ, Business Segments, Employee Strength)
15.2.4.2. Financial Overview
15.2.4.3. Product Portfolio
15.2.4.4. SWOT Analysis
15.2.4.5. Strategic Overview
15.2.5. Merck & Co., Inc.
15.2.5.1. Company Overview (HQ, Business Segments, Employee Strength)
15.2.5.2. Financial Overview
15.2.5.3. Product Portfolio
15.2.5.4. SWOT Analysis
15.2.5.5. Strategic Overview
15.2.6. Bristol-Myers Squibb Company
15.2.6.1. Company Overview (HQ, Business Segments, Employee Strength)
15.2.6.2. Financial Overview
15.2.6.3. Product Portfolio
15.2.6.4. SWOT Analysis
15.2.6.5. Strategic Overview
15.2.7. Anthera Pharmaceuticals, Inc.
15.2.7.1. Company Overview (HQ, Business Segments, Employee Strength)
15.2.7.2. Financial Overview
15.2.7.3. Product Portfolio
15.2.7.4. SWOT Analysis
15.2.7.5. Strategic Overview
15.2.8. ImmuPharma PLC
15.2.8.1. Company Overview (HQ, Business Segments, Employee Strength)
15.2.8.2. Product Portfolio
15.2.8.3. SWOT Analysis
15.2.8.4. Strategic Overview
15.2.9. Aurinia Pharmaceuticals, Inc.
15.2.9.1. Company Overview (HQ, Business Segments, Employee Strength)
15.2.9.2. Product Portfolio
15.2.9.3. SWOT Analysis
15.2.9.4. Strategic Overview
Note: Product cover images may vary from those shown
3 of 3

Loading
LOADING...

4 of 3
  • GlaxoSmithKline plc
  • F. Hoffmann-La Roche Ltd.
  • Pfizer, Inc.
  • AstraZeneca plc
  • Merck & Co., Inc.
  • Bristol-Myers Squibb Company
  • Anthera Pharmaceuticals, Inc.
  • ImmuPharma PLC
  • Aurinia Pharmaceuticals, Inc.
Note: Product cover images may vary from those shown
Adroll
adroll